OCGN - NASDAQ

Ocugen, Inc.

Ocugen, Inc.

OCGNยทNASDAQ

$1.34

-5.1%
HealthcareBiotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$453.62M
EPS-0.2300
P/E Ratio-5.97
Earnings Date07/30/2026
Ocugen, Inc.

Ocugen, Inc. Fair Value Envelope

OCGN ยท NASDAQ

Our analysis suggests that OCGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.34, this represents a potential HIDDEN relative to our calculated worth for Ocugen, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.34

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$123.5M
+ Cash & Equivalents$18.6M
Firm Value-$105.0M
- Debt$33.1M
Equity Value-$138.1M
/ Shares Outstanding312,320,112B
DCF Value-$0
OVERVALUED BY 133%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$42.4M
-$31.6M
-$23.5M
-$17.5M
-$13.0M
-$9.7M
-$7.2M
-$5.4M
-$4.0M
-$3.0M
Maintenance CapEx
-$27.6K
-$20.5K
-$15.3K
-$11.4K
-$8.5K
-$6.3K
-$4.7K
-$3.5K
-$2.6K
-$1.9K
Owner Earnings
-$42.4M
-$31.6M
-$23.5M
-$17.5M
-$13.1M
-$9.7M
-$7.2M
-$5.4M
-$4.0M
-$3.0M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$39.3M
-$27.1M
-$18.7M
-$12.9M
-$8.9M
-$6.1M
-$4.2M
-$2.9M
-$2.0M
-$1.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your OCGN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.